ArticleFrontiers in medicine2026
Real-world study on the effectiveness and breast safety analysis of hormone replacement therapy during menopause.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This real-world study evaluated the effects of 24-month menopausal hormone therapy (MHT) on bone mineral density (BMD), menopausal symptoms, and breast safety in postmenopausal women. Methods: A total of 809 postmenopausal patients aged 40-60 years receiving MHT from June 2021 to June 2022 were enrolled. Kuppermann scores, BMD, and breast findings were assessed at baseline and at 6, 12, 18, and 24 months. Changes in outcomes were analyzed across time points, with Bonferroni correction for Results: Over the 24-month period, the prevalence of osteoporosis and low bone mass decreased significantly from 18.0 to 14.0% and from 27.4 to 21.4%, respectively ( Conclusion: The 24-month MHT regimen effectively improved BMD, alleviated menopausal symptoms in a stage-dependent manner, and demonstrated a favorable breast safety profile. These findings support the role of MHT in the comprehensive management of postmenopausal health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.